Review



osteogenic differentiation medium dm  (Beijing Solarbio Science)


Bioz Verified Symbol Beijing Solarbio Science is a verified supplier
Bioz Manufacturer Symbol Beijing Solarbio Science manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Beijing Solarbio Science osteogenic differentiation medium dm
    SASP secreted by senescent BMSCs significantly promotes <t>osteogenic</t> differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD
    Osteogenic Differentiation Medium Dm, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 10045 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteogenic+differentiation+medium+dm/pmc12751491-113-1-16?v=Beijing+Solarbio+Science
    Average 99 stars, based on 10045 article reviews
    osteogenic differentiation medium dm - by Bioz Stars, 2026-08
    99/100 stars

    Images

    1) Product Images from "Senescent bone marrow mesenchymal stem cells exacerbate subchondral bone sclerosis and osteoarthritis via the senescence-associated secretory phenotype"

    Article Title: Senescent bone marrow mesenchymal stem cells exacerbate subchondral bone sclerosis and osteoarthritis via the senescence-associated secretory phenotype

    Journal: Stem Cell Research & Therapy

    doi: 10.1186/s13287-025-04833-1

    SASP secreted by senescent BMSCs significantly promotes osteogenic differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD
    Figure Legend Snippet: SASP secreted by senescent BMSCs significantly promotes osteogenic differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD

    Techniques Used: Staining, Control, Expressing

    Dasatinib + Quercetin treatment alleviates OA progression. A–C Representative images of Safranin O and Fast Green staining ( A ), H&E staining ( B ), and microCT ( C ) in sham and C-ACLT groups after treatment with D + Q. Scale bars, 100 μm for ( A ) and ( B ). Scale bars, 1 mm for ( C ). D The OARSI scores of sham and C-ACLT groups after treatment with D + Q. N = 5 mice per group. E–J Quantitative analysis of subchondral bone structural parameters, including BV/TV, SBP.Th, Tb.Pf, Tb.N, Tb.Sp, and Tb.Th. N = 5 mice per group. K Schematic diagram illustrating the mechanism by which senescent BMSCs promote osteogenic differentiation of normal BMSCs and subchondral bone sclerosis through SASPs. D + Q clears senescent BMSCs by inducing cell death and inhibits abnormal osteogenesis in OA subchondral bone. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD
    Figure Legend Snippet: Dasatinib + Quercetin treatment alleviates OA progression. A–C Representative images of Safranin O and Fast Green staining ( A ), H&E staining ( B ), and microCT ( C ) in sham and C-ACLT groups after treatment with D + Q. Scale bars, 100 μm for ( A ) and ( B ). Scale bars, 1 mm for ( C ). D The OARSI scores of sham and C-ACLT groups after treatment with D + Q. N = 5 mice per group. E–J Quantitative analysis of subchondral bone structural parameters, including BV/TV, SBP.Th, Tb.Pf, Tb.N, Tb.Sp, and Tb.Th. N = 5 mice per group. K Schematic diagram illustrating the mechanism by which senescent BMSCs promote osteogenic differentiation of normal BMSCs and subchondral bone sclerosis through SASPs. D + Q clears senescent BMSCs by inducing cell death and inhibits abnormal osteogenesis in OA subchondral bone. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD

    Techniques Used: Staining



    Similar Products

    osteogenic differentiation medium dm  (Beijing Solarbio Science)
    99
    Beijing Solarbio Science osteogenic differentiation medium dm
    SASP secreted by senescent BMSCs significantly promotes <t>osteogenic</t> differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD
    Osteogenic Differentiation Medium Dm, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteogenic+differentiation+medium+dm/pmc12751491-113-1-16?v=Beijing+Solarbio+Science
    Average 99 stars, based on 1 article reviews
    osteogenic differentiation medium dm - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    chondrogenic osteogenic differentiation medium (dm  (ScienCell)
    90
    ScienCell chondrogenic osteogenic differentiation medium (dm
    SASP secreted by senescent BMSCs significantly promotes <t>osteogenic</t> differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD
    Chondrogenic Osteogenic Differentiation Medium (Dm, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/osteogenic+differentiation+medium+dm/10__1016_slash_j__mtchem__2021__100720-46-76-83?v=ScienCell
    Average 90 stars, based on 1 article reviews
    chondrogenic osteogenic differentiation medium (dm - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    SASP secreted by senescent BMSCs significantly promotes osteogenic differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD

    Journal: Stem Cell Research & Therapy

    Article Title: Senescent bone marrow mesenchymal stem cells exacerbate subchondral bone sclerosis and osteoarthritis via the senescence-associated secretory phenotype

    doi: 10.1186/s13287-025-04833-1

    Figure Lengend Snippet: SASP secreted by senescent BMSCs significantly promotes osteogenic differentiation of normal BMSCs. A Schematic diagram of conditioned medium collection and the process of osteogenic differentiation induction. B-C Representative images and quantitative analysis of ALP and alizarin red staining in BMSCs treated with control osteogenic differentiation medium (DM + Con-CM) and senescent osteogenic differentiation medium (DM + Sn-CM). Scale bars, 500 μm. N = 3 samples per group. D-E Expression (D) and quantitative analysis of Alp, Runx2, Col1, and Ocn (E) proteins in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 3 samples per group. F The expression of core molecules in the osteogenic pathways in BMSCs treated with DM + Con-CM and DM + Sn-CM. N = 6 samples per group. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD

    Article Snippet: The osteogenic differentiation medium (DM) was formulated as follows: complete medium + 10 mM β-glycerophosphate (819-83-0, Solarbio, China) + 50 μg/ml ascorbic acid (50–81-7, Macklin, China) + 100 nM dexamethasone (ST1258-250 mg, Beyotime, China).

    Techniques: Staining, Control, Expressing

    Dasatinib + Quercetin treatment alleviates OA progression. A–C Representative images of Safranin O and Fast Green staining ( A ), H&E staining ( B ), and microCT ( C ) in sham and C-ACLT groups after treatment with D + Q. Scale bars, 100 μm for ( A ) and ( B ). Scale bars, 1 mm for ( C ). D The OARSI scores of sham and C-ACLT groups after treatment with D + Q. N = 5 mice per group. E–J Quantitative analysis of subchondral bone structural parameters, including BV/TV, SBP.Th, Tb.Pf, Tb.N, Tb.Sp, and Tb.Th. N = 5 mice per group. K Schematic diagram illustrating the mechanism by which senescent BMSCs promote osteogenic differentiation of normal BMSCs and subchondral bone sclerosis through SASPs. D + Q clears senescent BMSCs by inducing cell death and inhibits abnormal osteogenesis in OA subchondral bone. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD

    Journal: Stem Cell Research & Therapy

    Article Title: Senescent bone marrow mesenchymal stem cells exacerbate subchondral bone sclerosis and osteoarthritis via the senescence-associated secretory phenotype

    doi: 10.1186/s13287-025-04833-1

    Figure Lengend Snippet: Dasatinib + Quercetin treatment alleviates OA progression. A–C Representative images of Safranin O and Fast Green staining ( A ), H&E staining ( B ), and microCT ( C ) in sham and C-ACLT groups after treatment with D + Q. Scale bars, 100 μm for ( A ) and ( B ). Scale bars, 1 mm for ( C ). D The OARSI scores of sham and C-ACLT groups after treatment with D + Q. N = 5 mice per group. E–J Quantitative analysis of subchondral bone structural parameters, including BV/TV, SBP.Th, Tb.Pf, Tb.N, Tb.Sp, and Tb.Th. N = 5 mice per group. K Schematic diagram illustrating the mechanism by which senescent BMSCs promote osteogenic differentiation of normal BMSCs and subchondral bone sclerosis through SASPs. D + Q clears senescent BMSCs by inducing cell death and inhibits abnormal osteogenesis in OA subchondral bone. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. All data are presented as mean ± SD

    Article Snippet: The osteogenic differentiation medium (DM) was formulated as follows: complete medium + 10 mM β-glycerophosphate (819-83-0, Solarbio, China) + 50 μg/ml ascorbic acid (50–81-7, Macklin, China) + 100 nM dexamethasone (ST1258-250 mg, Beyotime, China).

    Techniques: Staining